Headquarters: Zug, Switzerland
CHF as of July 1, 2023
|Company||Market Cap (USD)|
|Zoetis Inc.||$78.54 B|
|MERCK Kommanditgesellschaft auf Aktien||$70.69 B|
|Takeda Pharmaceutical Company Limited||$46.59 B|
|Haleon plc||$37.99 B|
|Eisai Co. Ltd||$17.26 B|
PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development, and in generic products. It engages in manufacturing custom research grade peptides for use in pre-clinical and clinical development, as well as for regulatory and scientific studies; and developing neoantigen therapies as personalized immunotherapies. The company is also involved in manufacturing peptides for commercially approved peptide therapeutics; and provision of consultation services. In addition, it manufactures peptide-based generics for human and veterinary markets; and cosmetic peptides. Further, the company offers regulatory affair support services. The company was founded in 1952 and is headquartered in Zug, Switzerland. PolyPeptide Group AG operates as a subsidiary of Draupnir Holding B.V.
PolyPeptide Group AG has the following listings and related stock indices.
Stock: SIX: PPGN